BIO-RAD LABORATORIES, INC. BIO
NYSE · XNYS · stock · Laboratory Analytical Instruments
Chart by TradingView
5/9
Piotroski F — financial health
6.54
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $2.6B | $759.9M | $1.3B | $374.6M | $7.5B |
| 2024 | $2.6B | -$1.8B | $1.4B | $289.6M | $6.6B |
| 2023 | $2.7B | -$637.3M | $1.4B | $218.2M | $8.7B |
| 2022 | $2.8B | -$3.6B | $1.6B | $81.6M | $9.6B |
| 2021 | $2.9B | $4.3B | $1.6B | $535.7M | $13.7B |
| 2020 | $2.5B | $3.8B | $1.4B | $476.4M | $9.9B |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 6.54 (safe)
- Working capital / assets 0.226
- Retained earnings / assets 0.773
- EBIT / assets 0.004
- Equity / liabilities 2.387
Source: SEC EDGAR filings · CIK 0000012208 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.